Author:
Wang Zhanqing,Chi Lili,Shen Yaling
Funder
National Natural Science Foundation of China
Shanghai Leading Academic Discipline Project
Research Program of State Key Laboratory of Bioreactor Engineering
Publisher
Springer Science and Business Media LLC
Subject
Drug Discovery,Molecular Medicine,Biochemistry,Bioengineering,Analytical Chemistry
Reference28 articles.
1. Baselga J, Norton L, Albanell J, Kim YM, Mendelsohn J (1998) Recombinant humanized Anti-HER2 antibody (Herceptin™) enhances the antitumor activity of paclitaxel and doxorubicin against HER2/neu overexpressing human breast cancer xenografts. Cancer Res 58:2825–2831
2. Brinkmann U (2000) Recombinant antibody fragments and immunotoxin fusions for cancer therapy. Vivo 14:21
3. Butt TR, Edavettal SC, Hall JP, Mattern MR (2005) SUMO fusion technology for difficult-to-express proteins. Protein Expres Purif 43:1–9
4. Cao Y, Marks JW, Liu Z, Cheung LH, Hittelman WN, Rosenblum MG (2013) Design optimization and characterization of Her2/neu-targeted immunotoxins: comparative in vitro and in vivo efficacy studies. Oncogene 33:429–439
5. Chen X, Zaro JL, Shen W-C (2013) Fusion protein linkers: property, design and functionality. Adv Drug Deliv Rev 65:1357–1369
Cited by
3 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献